Navigation Links
Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule
Date:2/17/2011

FRANKLIN, Mass., Feb. 17, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, announced that development of the commercially ready Symphony tCGM System is ahead of schedule.  The company said that the system will be ready for demonstration in the second quarter and it will be used in a clinical trial shortly thereafter, replacing the prototype used in earlier clinical trials.  

Echo said it anticipates that upon completion of the development work no further changes will be made to the Symphony tCGM System, and that the device will be the one used for sale, subject to positive clinical studies and FDA market clearance of the product.  The addressable market for needle-free, continuous wireless glucose monitoring in the hospital critical care setting exceeds $1 billion annually and the global glucose monitoring market exceeds $12 billion annually.

"With the successful completion of our recent financing we now have sufficient capital to accelerate the product development work of our Symphony tCGM System," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.  "We are now prepared to complete our final development work and clinical validation.  This next generation Symphony device incorporates substantial improvements beyond the prototype used in earlier studies and we look forward to validating those improvements in clinical testing."  

The Symphony tCGM System incorporates Echo's proprietary Prelude SkinPrep System, with a noninvasive wireless biosensor and a wireless monitor or handheld device for needle-free, continuous monitoring of glucose levels.  

About Echo TherapeuticsEc
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
2. Prime Therapeutics Vice President of Specialty Pharmacy Solutions Speaks at 16th Annual PBMI Drug Benefit Conference
3. Echo Therapeutics Announces Appointments to Board of Directors
4. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
5. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
6. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
7. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
8. Prime Therapeutics President and CEO Eric Elliott Presents Keynote Address at 2011 PCMA Managed Markets Educational Forum
9. NewCardio Study of QTinno Accuracy Selected for Presentation at the National Scientific Meeting of the American Society of Clinical Pharmacology and Therapeutics
10. DSM and NKT Therapeutics Sign Contract for Lead Product Development and Manufacture
11. JumpStart Ventures and Cleveland Clinic Invest in SironRX Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 The Temple Health & Bioscience District ... 5,000-square-foot building at 1802 South First St. in the Temple ... the City of Temple to receive ... the Central Texas Veterans Health Care System, the new facility ... early stage biotechnology and life science companies. ...
(Date:3/27/2015)... March 27, 2015 A new report from Kalorama ... – Chile , ... top targets for IVD firms.  The healthcare research firm said ... IVD strategies for the Latin American continent with a population ... distributed supply operations. However, the country,s regional economic clout does ...
(Date:3/27/2015)... LAS VEGAS , March 27, 2015 Zimmer ... more efficient external fixation system for trauma patients. ... the XtraFix ® External Fixation System from ... design technology and materials.   The XtraFix ... and clamps from the external fixation process, resulting in saved ...
Breaking Medicine Technology:Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3
... Transdermal System CIII 20 mcg/hour provided significantly ... compared to Butrans 5 mcg/hour when used in opioid-experienced ... according to a pivotal Phase 3 clinical study published ... of Pain . (Logo: http://photos.prnewswire.com/prnh/20100921/NY67262) ...
... SILVER SPRING, Md., Sept. 23, 2011 The U.S. ... treat patients with atypical Hemolytic Uremic Syndrome (aHUS), a ... kidney (renal) failure and is also associated with increased ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Atypical HUS accounts ...
Cached Medicine Technology:Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 2Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 3Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 4Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 5Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 6FDA Approves Soliris for Rare Pediatric Blood Disorder 2FDA Approves Soliris for Rare Pediatric Blood Disorder 3
(Date:3/29/2015)... 2015 The Contract Research Organizations ... research, manage data results and help develop and ... regulation standards. Contract research organizations (CROs) mainly serve ... sectors. Industry operators provide clients with a full ... research for Food and Drug Administration (FDA) approval. ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 North American ... PT Online Continuing Education Courses . ... hours of CME - TPTA, approval # 56399TX      ... evaluation of the shoulder complex - 10.5 hours - ... #56400TX , Examination and Treatment of the SI Joint ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 "Necrorun" was ... which takes a look at the latest and coolest ... Joe Troohey, the host of NewsWatch and technology expert, ... this is an entertaining endless runner game with knights, ... game was released in 2009, according to Eurogamer. The ...
(Date:3/28/2015)... Emergency Medical Care (EMC), a New ... recently commemorated its three-year anniversary of being the only ... to 24-hour urgent care, Emergency Medical Care offers its ... time, Emergency Medical Care’s Urgent Care NYC ... eye injuries, ear infections, fevers, insect bites, burns, animal ...
(Date:3/28/2015)... 28, 2015 One in three young ... research presented today at the American Orthopaedic Society for ... examined the long term success of surgery for patients ... survey data from 242 patients who underwent ACL reconstruction ... Roe, MBBS, FRACS, from North Sydney Orthopaedic and Sports ...
Breaking Medicine News(10 mins):Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2
... Jan. 3 Continuing its role as ... organizations, the,American Association of Preferred Provider Organizations ... Care Administrators Association,(HCAA) that will significantly enhance ... consolidation and increased consumerism continue to fuel,further ...
... and Hispanic ethnic groups and others with a family history of ... glaucoma are particularly vulnerable, ... have no early symptoms and do not notice as their peripheral,vision ... the,three million Americans with the disease are unaware of their condition.,January ...
... In an era of expanding competition,from generics, expiring ... in new drug discoveries, there is very little ... report by Kalorama Information entitled Drug,Pricing and Reimbursement ... companies the information they need to,reevaluate their pricing ...
... 3 RxElite, Inc. (OTC,Bulletin Board: RXEI), a ... products, announced today that a registration,statement covering the ... effective by the Securities and Exchange Commission on ... informational purposes only, and does not,represent a solicitation ...
... finds one-hour session produces as much carbon monoxide as a ... A leisurely hour of puffs from a hookah -- a ... -- packs the same carbon monoxide punch as a pack-a-day ... looks at a single toxic gas, making it impossible to ...
... Emory University have developed a novel anti-tumor compound that represents ... points" for cancer cells. , The results of research on ... of Cancer Research. The article is highlighted on the cover. ... human patients with solid tumors in 2007. , The idea ...
Cached Medicine News:Health News:AAPPO and HCAA Form Partnership to Enhance Services to Meet the Changing Business Needs of PPOs and TPAs 2Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 2Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 3Health News:Generic Onslaught Makes Drug Pricing Decisions More Critical Than Ever 2Health News:RxElite Registration Statement Declared Effective by Securities and Exchange Commission 2Health News:Hookah Smoking as Tough on Lungs as Cigarettes 2Health News:Hookah Smoking as Tough on Lungs as Cigarettes 3Health News:Novel anticancer strategy moves from laboratory to clinic 2Health News:Novel anticancer strategy moves from laboratory to clinic 3
... EVLT, the #1 physician choice in ... advantages to remedying superficial vein reflux. EVLT ... to surgical vein stripping that effectively and ... laser fiber to occlude the vein. The ...
... Aculens 186 UV combines the latest technology ... measurement of ultra violet transmission and auto ... is also programmed to network with the ... Instruments, today, or in the future. , ...
Inquire...
...
Medicine Products: